High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid Tumors

Cancer

Volumn 100, Issue 3, 2004, Pages 612-620

  Hansmann, Anika ^a   Adolph, Claudia ^a   Vogel, Tilmann ^a   Unger, Andreas ^a   Moeslein, Gabriela ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aggressive fibromatosis; Desmoid tumor; Extracolonic manifestation; Familial adenomatous polyposis (FAP); Tamoxifen therapy

Indexed keywords

RALOXIFENE; SULINDAC; TAMOXIFEN;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CHILD; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DESMOID TUMOR; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE; WEIGHT GAIN;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROMATOSIS, ABDOMINAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SULINDAC; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 1642524320     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11937     Document Type: Article

References (49)

1. Muller J. Ueber den feinen Bau und die Formen der 124 krankhaften Geschwulste [About the fine structure and types of pathological tumors]. Berlin: Reimer G. Erste Lieferung. 1838:60.
2. Naylor EW, Gardner EJ, Richards RC. Desmoid tumors and mesenteric fibromatosis in Gardner's syndrome: report of kindred 109. Arch Surg. 1979;114:1181-1185.
3. Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. Incidence, sex, age and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77:665-673.
4. Farmer KC, Hawley PR, Phillips RK. Desmoid disease. In: Phillips RK, Spigelman AD, Thomson JP, editors. Familial adenomatous polyposis and other polyposis syndromes. London: Edward Arnold. 1994:128-142.
5. Nichols RW. Desmoid tumors: a report of 31 cases. Arch Surg. 1923;7:227-236.
6. Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet. 1951;3:167-176.
7. Smith WG. Multiple polyposis, Gardner's syndrome, and desmoid tumors. Dis Colon Rectum. 1958;1:323-332.
8. Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer. 1994;74:1270-1274.
9. Jones IT, Jagelman DG, Fazio VW, Lavery IC, Weakley FL, McGannon E. Desmoid tumors in familial polyposis coli. Ann Surg. 1986;204:94-97.
10. Harvey JC, Quan SH, Fortner JG. Gardner's syndrome complicated by mesenteric desmoid tumors. Surgery. 1979;85:475-477.
11. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989;210:765-769.
12. Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S. Changing causes of mortality in patients with FAP. Dis Colon Rectum. 1996;39:384-387.
13. Klemmer S, Pascoe L, DeCosse J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet. 1987;28:385-392.
14. Caspari R, Olschwang S, Mandl M, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. 1995;4:337-340.
15. Hamilton L, Blackstein M, Berk T, et al. Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Can J Surg. 1996;39:247-252.
16. Wilcken N, Tattersall MH. Endocrine therapy for desmoid tumors. Cancer. 1991;68:1384-1388.
17. Jones IT, Jagelman DG, Fazio VW, Lavery IC, Weakley FL, McGannon E. Desmoid tumors in familial polyposis coli. Ann Surg. 1986;204:94-97.
18. Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg. 1991;161:416-421.
19. Klein WA, Miller HH, Anderson M, DeCossec JJ. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer. 1987;60:2863-2868.
20. Suit H, Spiro I. Radiation in the multidisciplinary management of desmoid tumors. Front Radiat Ther Oncol. 2001;35:107-119.
21. Khorsand J, Karakousis CP. Desmoid tumors and their management. Am J Surg. 1985;149:215-218.
22. Dominguez-Malagon HR, Alfeiran-Ruiz A, Chavarria-Xicotencatl P, Duran-Hernandez MS. Clinical and cellular effects of colchicine in fibromatosis. Cancer. 1992;69:2478-2483.
23. Moeslein G, Dozois RR. Desmoid tumors associated with familial adenomatous polyposis-continuing controversies. Perspect Colon Rectal Surg. 1996;10:109-125.
24. Shen TY, Winter CA. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res. 1977;12:90-245.
25. Duggan DE, Hooke KF, Noll RM, Hucker HB, Van Arman CG. Comparative disposition of sulindac and metabolites in five species. Biochem Pharmacol. 1978;27:2311-2320.
26. Love R, Mazess R, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-856.
27. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77:674-680.
28. Mohos E, Kovacs T, Brittig F, Nagy A. [Desmoid tumors in three patients (review)] [in Hungarian]. Magy Seb. 2001;54:387-392.
29. Friedl W, Caspari R, Sengteller R, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis' Experience from 680 FAP families. Gut. 2001;48:515-521.
30. Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95:102-107.
31. Karakousis CP, Mayordomo J, Zografos GC. Desmoid tumors of the trunk and extremity. Cancer. 1993;72:1637-1641.
32. Spear MA, Jennings LC, Mankin HJ. Individualizing management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 1998;40:637-645.
33. Berk T, Cohen Z, McLeod RS, Stern HS. Management of mesenteric desmoid tumours in familial adenomatous polyposis. Can J Surg. 1992;35:393-395.
34. Lotfi AM, Dozois RR, Gordon H, et al. Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int J Colorectal Dis. 1989;4:30-36.
35. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg. 1996;83:1494-1504.
36. Pikaar A, Nortier JW, Griffioen G, Vasen HF. Desmoid tumors in patients with familial adenomatous polyposis. Ned Tijdschr Geneeskd. 2002;20; 146:29 1355-1359.
37. Church J, McGannon E. Prior pregnancy ameliorates the course of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis. Dis Colon Rectum. 2000;43:445-450
38. Lim CL, Walker MJ, Mehta RR, Das Gupta TK. Estrogen and antiestrogen binding sites in desmoid tumors. Eur J Cancer Clin Oncol. 1986;22:583-587.
39. Svanvik J, Knutsson F, Jansson R, Ekman H. Desmoid tumor in the abdominal wall after treatment with high dose estradiol for prostatic cancer. Acta Chir Scand. 1982;148:301-303.
40. Mukherjee A, Malcolm A, de la Hunt M, Neal DE. Pelvic fibromatosis (desmoid)-treatment with steroids and tamoxifen. Br J Urol. 1995;75:559-560.
41. Gagliardi A., Henig B, Collins DC. Antiestrogen inhibit endothelial cell growth stimulated by angiogenic growth factor. Anticancer Res. 1996;16:1101-1106.
42. Benson JR, Baum M. Breast cancer, desmoid tumours, and familial adenomatous polyposis-a unifying hypothesis. Lancet. 1993;342:848-850.
43. Brooks MD, Ebbs SR, Colletta AA, Baum M. Desmoid tumors treated with triphenylethylenes. Eur J Cancer. 1992;28A: 1014-1018.
44. Lackner H, Urban C, Kerbl R, Schwinger W, Beham A. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer. 1997;80:334-340.
45. Bauernhofer T, Stöger H, Schmid M, et al. Sequential treament of recurrent mesenteric desmoid tumor. Cancer. 1996;77:1061-1065.
46. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer. 1983;52:2201-2204.
47. Hial V, Horakova Z, Shaff FE, Beaven MA. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol. 1976;37:367-376.
48. Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999;86:1185-1189.
49. Belliveau P, Graham MA. Mesenteric desmoid tumor in Gardner's syndrome treated by sulindac. Dis Colon Rectum. 1984;27:53-54.